Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001641172-25-010798
Filing Date
2025-05-15
Accepted
2025-05-15 15:40:54
Documents
66
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q form10-q.htm   iXBRL 10-Q 1738026
2 EX-31.1 ex31-1.htm EX-31.1 10852
3 EX-32.1 ex32-1.htm EX-32.1 4794
  Complete submission text file 0001641172-25-010798.txt   9038855

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE ppcb-20250331.xsd EX-101.SCH 59597
5 XBRL CALCULATION FILE ppcb-20250331_cal.xml EX-101.CAL 62907
6 XBRL DEFINITION FILE ppcb-20250331_def.xml EX-101.DEF 294466
7 XBRL LABEL FILE ppcb-20250331_lab.xml EX-101.LAB 485554
8 XBRL PRESENTATION FILE ppcb-20250331_pre.xml EX-101.PRE 393681
68 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 1332180
Mailing Address 302/6 BUTLER STREET CAMBERWELL, VICTORIA C3 3124
Business Address 302/6 BUTLER STREET CAMBERWELL, VICTORIA C3 3124 61-03-9882-0780
Propanc Biopharma, Inc. (Filer) CIK: 0001517681 (see all company filings)

EIN.: 330662986 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 000-54878 | Film No.: 25952047
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)